1. Mycobacterium abscessus Infection During Ustekinumab Treatment in Crohn's Disease: A Case Report and Review of the Literature
- Author
-
H H Tan, Jenny G. Low, Hang Hock Shim, Khoon Lin Ling, Sophie Carrie Shan Cai, and Webber Chan
- Subjects
Tuberculosis ,Side effect ,Injections, Subcutaneous ,Mycobacterium Infections, Nontuberculous ,Disease ,Mycobacterium abscessus ,Antibodies, Monoclonal, Humanized ,Drug Administration Schedule ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Cefoxitin ,0302 clinical medicine ,Crohn Disease ,Ustekinumab ,medicine ,Humans ,030212 general & internal medicine ,Amikacin ,Crohn's disease ,biology ,business.industry ,Ileal Diseases ,Interleukin-12 Subunit p40 ,Gastroenterology ,Nontuberculous Mycobacteria ,General Medicine ,Middle Aged ,biology.organism_classification ,medicine.disease ,Magnetic Resonance Imaging ,Anti-Bacterial Agents ,Clinical trial ,Treatment Outcome ,Thigh ,Immunology ,Female ,business ,Mycobacterium ,medicine.drug - Abstract
The introduction of ustekinumab, an interleukin [IL]12/23 p40 inhibitor, to the therapeutic armamentarium of Crohn's disease has provided a much needed treatment option for patients who have failed conventional biologics with anti-tumour necrosis factor [TNF] and anti-integrin agents. Despite targeting two major cytokine pathways, the side effect profile of ustekinumab appears to be favourable in clinical trials. In particular, the risk of tuberculosis infection was observed to be lower than in patients who have received anti-TNF agents. The risk of non-tuberculosis mycobacterium infection, however, remains unknown. Here, we report the first case of a patient with Crohn's disease who developed Mycobacterium abscessus infection while on ustekinumab treatment.
- Published
- 2018